The small-cap biotech sector has been somewhat en fuego here in the fourth quarter, as seen in the SPDR S&P Biotech ETF (XBI) . One thing helping buoy sentiment in this space is the pickup in merger-and-acquisition (M&A) activitySo far just this week, we have had Merck & Co(MRK) agreeing to acquire ArQule Inc(ARQL) for $2.7 billion at a buyout pre...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.